Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Genmab is a leading biotechnology company, with a strong pipeline and key partnerships with major pharmaceutical companies. DCF valuation yields a 12-month price target of $40 per share. Risks include slowing sales of Genmab's leading product, negative results from trials for other products, and currency and macro risks. Recent positive clinical data for EPKINLY in 1L DLBCL reduce risk for ongoing trials, leading to a reiteration of a Buy rating and a raised 12-month price target of $38 per share.

Bears say

Genmab is partnered with multiple large pharma companies for its lead products, which may create a potential overdependence on these partners for its revenue. Furthermore, the company faces significant risks in the form of potential setbacks in R&D, regulatory issues, legal challenges, and commercialization. Additionally, the company's heavy investment in acquisitions, including the recent MRUS acquisition, may lead to financial risks in the future. Based on our DCF-based valuation, we arrived at a price objective of $38 per share, but this outlook may change based on factors such as slowing sales of DARZALEX, negative results from EPKINLY trials, and potential failures of other products in clinical testing. These risks may lead to dilution of the company's equity, creating further downward pressure on the stock.

GMAB has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 8 analysts, GMAB has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.